Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.

For more information regarding these topics please click the links below. For questions on these grant opportunities, please contact Daniel Frank, Health Science Administrator, Tuberculosis Clinical Research Branch, NIAID at daniel.frank@nih.gov .

• Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21; PAR-19-364): https://grants.nih.gov/grants/guide/pa-files/PAR-19-364.html
• Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01; PAR-19-357): https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html